Back to search results

Collecting Samples for HIV/AIDS-Related Cancer Research

This study is collecting blood and tissue samples to help researchers understand the connection between HIV and certain cancers. By studying these samples, doctors hope to learn more about how biological or genetic factors are related to HIV and cancers that commonly affect people living with HIV. You may be able to join if you are at least 18 years old and are HIV-positive with a cancer diagnosis. If you are HIV-negative, you might still be eligible if you have a newly diagnosed or returning cancer that is known to be linked to AIDS-associated cancers, like classic Kaposi sarcoma. The main goal is to collect a certain number of these samples over about 10 years to support future research.

Study design
This is an observational study aiming to enroll 200 participants. It is not testing a new treatment, but rather collecting samples for research.
What's involved
You would be asked to donate blood once. You may also donate tissue samples, either from a past procedure or an upcoming one.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05663502

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Recruiting
Not specifiedAges 18+Observational
AIDS Malignancy Consortium
~200 participants
Updated 2026-06-01 on ClinicalTrials.gov
What's tested:Biospecimen Collection

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of biospecimens collected
Measured over Through study completion, anticipated to be 10 years

Conditions

Anal Carcinoma
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Kaposi Sarcoma
Lymphoma
Malignant Solid Neoplasm
Multicentric Castleman Disease
Plasmablastic Lymphoma
Recurrent Kaposi Sarcoma
Recurrent Lymphoma
Recurrent Plasmablastic Lymphoma
Transplant-Related Kaposi Sarcoma

Explore related trials

Anal CarcinomaHematologic NeoplasmHIV InfectionKaposi SarcomaLymphomaMulticentric Castleman DiseaseSolid NeoplasmX-linked Lymphoproliferative Syndrome 1

NCT05663502

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • George Washington University

    Washington D.C., District of Columbiastudy coordinator listed

    Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utahstudy coordinator listed

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Mount Sinai Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Marylandstudy coordinator listed

    Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, Californiastudy coordinator listed

    Recruiting

  • University of California, San Francisco

    San Francisco, Californiastudy coordinator listed

    Recruiting

  • University of Miami

    Miami, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jeff Bethony · PRINCIPAL_INVESTIGATOR · AIDS Malignancy Consortium

Who to contact

Erin Reid, MD
[email protected]
858-822-5354
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be at least 18 years of age
Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as:
classic Kaposi sarcoma
transplant-associated Kaposi sarcoma,
anal cancer,
multicentric Castleman's disease,
Epstein Barr Virus (EBV) -positive lymphoma
plasmablastic lymphoma
Hodgkin's lymphoma.
For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: :
Documentation of HIV diagnosis in the medical record by a licensed health care provider;
Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \[e.g., Truvada\], which is exclusionary);
HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \> 1000 RNA copies/mL;
Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay.
Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer.
The investigator determines that the participant (or his/her legally authorized representative \[LAR\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.

What this trial measures

  • Number of biospecimens collectedThrough study completion, anticipated to be 10 years

    The number of blood and tissue specimens will be counted.